Compass Therapeutics holders back all 2026 proposals

Compass Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 10, 2026.

Rhea-AI Filing Summary

Compass Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 10, 2026. Stockholders elected Class III directors Thomas J. Schuetz and Richard S. Lindahl to serve until the 2029 annual meeting. They also ratified CohnReznick LLP as independent registered public accounting firm for the year ending December 31, 2026, with 137,896,097 votes for and 181,037 against. On a non-binding basis, stockholders approved executive compensation, with 117,963,684 votes for and 1,796,022 against, and voted to hold future advisory votes on executive compensation every year, with 118,289,260 votes favoring an annual frequency.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Schuetz: 102,984,184 votes Votes for Lindahl: 103,453,540 votes Auditor ratification for votes: 137,896,097 votes +4 more

7 metrics

Votes for Schuetz 102,984,184 votes Election of director Thomas J. Schuetz, Class III

Votes for Lindahl 103,453,540 votes Election of director Richard S. Lindahl, Class III

Auditor ratification for votes 137,896,097 votes Ratification of CohnReznick LLP for year ending December 31, 2026

Auditor ratification against votes 181,037 votes Votes against CohnReznick LLP ratification

Say-on-pay for votes 117,963,684 votes Non-binding advisory approval of executive compensation

Say-on-pay against votes 1,796,022 votes Non-binding advisory vote against executive compensation

Annual frequency votes 118,289,260 votes Preference for holding say-on-pay votes every year

Key Terms

broker non-votes, non-binding, advisory basis, independent registered public accounting firm, emerging growth company, +1 more

5 terms

broker non-votes financial

"For | | Against | | Abstain | | Broker Non-votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

non-binding, advisory basis financial

"The stockholders voted to approve, on a non-binding, advisory basis,"

A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.

independent registered public accounting firm financial

"ratified the appointment of CohnReznick, LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

definitive proxy statement regulatory

"A more detailed description of each proposal is set forth in the Company’s definitive proxy statement"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Compass Therapeutics (CMPX) stockholders approve at the 2026 annual meeting?

Stockholders approved all proposals, including electing two Class III directors, ratifying CohnReznick LLP as auditor, approving executive compensation on an advisory basis, and choosing to hold future say-on-pay votes every year.

How did Compass Therapeutics (CMPX) vote on the election of directors?

Stockholders elected Thomas J. Schuetz and Richard S. Lindahl as Class III directors to serve until the 2029 annual meeting, each receiving over 103 million votes for and more than 18 million votes withheld, plus broker non-votes.

Was the auditor ratification for Compass Therapeutics (CMPX) approved?

Yes, stockholders ratified CohnReznick LLP as independent registered public accounting firm for the year ending December 31, 2026, with 137,896,097 votes for, 181,037 against, and 5,064,867 votes withheld, with no broker non-votes reported.

How did Compass Therapeutics (CMPX) stockholders vote on executive compensation?

In the advisory say-on-pay vote, 117,963,684 votes were cast in favor of named executive officer compensation, 1,796,022 against, and 2,061,977 abstentions, with 21,320,318 broker non-votes, indicating stockholder support on a non-binding basis.

What frequency did Compass Therapeutics (CMPX) investors choose for future say-on-pay votes?

Stockholders voted to hold advisory votes on executive compensation every year, with 118,289,260 votes for annual, 811,275 for every two years, 1,491,631 for every three years, and 1,229,517 abstentions. The board aligned with this annual frequency decision.

Will Compass Therapeutics (CMPX) always hold annual say-on-pay votes going forward?

The board decided to provide an annual advisory vote on executive compensation consistent with stockholder preference, while reserving the ability to change this frequency later if it determines a different schedule better serves stockholders’ interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:00 PM Learn about SEC filing dates

false 0001738021 0001738021 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2026

COMPASS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-39696	82-4876496
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

80 Guest Street, Suite 601

Boston, Massachusetts 02135

(Address of Principal Executive Offices) (Zip Code)

(617) 500-8099

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CMPX	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 10, 2026 Compass Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. The final results for each of the matters submitted to a vote of stockholders at the meeting are set forth below. A more detailed description of each proposal is set forth in the Company’s definitive proxy statement on Form DEF 14A, filed with the U.S. Securities and Exchange Commission on April 29, 2026.

Proposal No. 1. Election of Directors. The stockholders elected the two Class III nominees for director to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below:

Name		For		Withheld		Broker Non-votes
Thomas J. Schuetz, M.D., Ph.D.		102,984,184		18,837,499		21,320,318
Richard S. Lindahl, M.B.A.		103,453,540		18,368,143		21,320,318

Proposal No. 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the votes set forth in the table below:

For		Against		Withheld		Broker Non-votes
137,896,097		181,037		5,064,867		-

Proposal No. 3. Non-binding, Advisory Vote on the Compensation of our Named Executive Officers. The stockholders voted to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, by the votes set forth in the table below:

For		Against		Abstain		Broker Non-votes
117,963,684		1,796,022		2,061,977		21,320,318

Proposal No. 4. Non-binding, Advisory Vote on the Holding of the Future Advisory Votes on the Compensation of our Named Executive Officers. The stockholders voted, on a non-binding, advisory basis, to hold such advisory votes annually, by the votes set forth in the table below:

Every Year		Every Two Years		Every Three Years		Abstain
118,289,260		811,275		1,491,631		1,229,517

Based on the voting results at the Annual Meeting, and consistent with the recommendation of the board of directors as set forth in our proxy statement for the Annual Meeting, the board of directors has determined to provide for a stockholder advisory vote on executive compensation on an annual basis; provided that, in the future, the board of directors may determine whether a different frequency for such advisory votes is in the best interests of the Company’s stockholders.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Compass Therapeutics, Inc.
June 11, 2026	By:	/s/ NEIL LERNER
		Neil Lerner
		Chief Accounting Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.9 KB